Zirconium (89Zr) crefmirlimab berdoxam

Download press release Los Angeles, CA, USA, Dec 16, 2021 – ImaginAb, Inc., a market leading global biotechnology company focused on developing next generation ImmunoPET imaging agents and therapeutic radiopharmaceuticals (RPT), today announced the signing of a new multi-year, non-exclusive license agreement with Bayer. Under the agreement, ImaginAb will license and supply clinical doses of its investigational CD8 ImmunoPET technology (zirconium Zr 89 crefmirlimab berdoxam) to Bayer for use in the clinical development of several of its investigational novel oncology assets at clinical sites across multiple countries. Commenting on the announcement, Ian Wilson, Chief Executive Officer of ImaginAb said “We are excited that Bayer will incorporate our CD8 ImmunoPET technology in their clinical trials. Working closely together, our aim is to understand therapeutic efficacy and treatment outcomes in cancer patients in clinical trials more precisely and earlier.” “ImaginAb is actively investing in the clinical and global supply chain development of its CD8 ImmunoPET (zirconium Zr 89 crefmirlimab berdoxam) technology to provide simple access to this novel and market leading investigational technology,” Wilson continued. “Our ultimate goal is to gain regulatory approval of this technology in multiple geographies that will enable the widespread use and adoption of 89Zr-Df-crefmirlimab to ultimately help patients find the best oncology treatment for their cancer. Working with leading pharmaceutical companies on clinical trials such as Bayer will help us achieve our vision.” “CD8 T cells play such a pivotal role in immunotherapy of many cancers and zirconium Zr 89 crefmirlimab berdoxam is becoming one of the most widely used PET imaging technologies by pharmaceutical and biotech companies in CIT clinical trials to track CD8 cells in study subjects.”

LOS ANGELES and SAN DIEGO, Jan. 28, 2021 /PRNewswire/ -- ImaginAb Inc, a leading global provider of immuno-oncology imaging agents and NEUVOGEN, an immuno-oncology company developing next generation therapeutic whole cell cancer vaccines, announced they have signed a multi-year non-exclusive licensing agreement. Under the terms of the agreement, ImaginAb will work with NEUVOGEN to implement clinical doses of 89Zr CD8 Immuno-PET imaging agents into their therapeutic vaccine clinical trials, and provide technical and clinical support to NEUVOGEN's development teams. ImaginAb will receive license fees and other contingent payments. No other terms were disclosed. ImaginAb's PET imaging technology enables tracking and quantitative imaging of CD8 T cells in cancer patients, enabling confirmation of drug mechanism and indication of the cancer immunotherapies' efficacy. Previous clinical studies have shown the clinical relevance of ImaginAb's 89Zr CD8 Immuno-PET imaging agent, and the use of these imaging data sets potentially contributes to improving the standard of care in immune-oncology therapies. The company's goal is to enable widespread use and adoption of 89Zr CD8 Immuno-PET technology. ImaginAb's CEO, Ian Wilson, commented: "We are delighted and very excited to work with NEUVOGEN and support the clinical development of their novel therapeutic cancer vaccine candidates. CD8 T cells play a pivotal role in cancer immunotherapy and our clinical studies have shown our 89Zr CD8 Immuno-PET imaging agent tracks and quantifies CD8 T cells in patients. We believe combining CD8 imaging with NEUVOGEN's whole cell cancer vaccines will enable more robust clinical data sets and accelerate the development of novel treatment protocols for solid tumors." NEUVOGEN's next-generation whole cell cancer vaccines are designed to simultaneously prime the broadest array of tumor targets, impacting multiple biologic pathways with the goal of directing an immune response against overlapping targets on every cell within a tumor. ImaginAb's T Cell specific PET imaging technology allows the NEUVOGEN team to visualize Tumor Infiltrating Lymphocytes, and monitor the dynamics of CD8 T cells in response to its novel cancer vaccine therapies, without the need for multiple tumor biopsies. "This agreement provides NEUVOGEN access to highly specific and precise imaging of the presence of CD8 T Cells in solid tumors over time." said Todd Binder, Chief Executive Officer, NEUVOGEN. "ImaginAb's 89Zr CD8 Immuno-PET imaging agent will help our development teams determine changes in CD8 T cell tumor infiltrates induced by NEUVOGEN's therapies, an important indicator of a patient's successful immune response to our vaccine therapy." About ImaginAb ImaginAb Inc. is a market leading biotechnology company focused on developing radiopharmaceutical imaging and therapy agents. ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full-length antibodies while remaining biologically inert in the body. Used with widely available PET scan technology, these novel minibodies illuminate high-value molecular targets, providing physicians with a whole-body picture of immune activity. ImaginAb is advancing a pipeline of minibodies against oncology and immunology targets including the 89Zr CD8 ImmunoPET targeting CD8 T cells. ImaginAb's products have the potential to improve patient care and lower healthcare costs. The Company is backed by top tier venture capital firms and strategic corporate firms including, Adage Capital, The Cycad Group, Norgine ventures Jim Pallotta of the Raptor Group, The Parker Institute for Cancer Immunotherapy, and Merck (MSD) Pharma. For more information about ImaginAb's pipeline and technology, visit . About CD8 Immuno-PET The 89Zr CD8 Immuno-PET agent ([89Zr]-Df-IAB22M2C) is a Zirconium-89 labelled minibody that binds the CD8 receptor on human T cells and is used for quantitative, non-invasive PET imaging of CD8 T cells in patients. CD8 T cells are the main effector cells involved in the immune response against tumor cells induced by immunotherapies and they also play a key role in multiple autoimmune diseases. As such, quantitative imaging of CD8 T cells can be used to diagnose the immune status of a patient, to measure the efficacy of immunotherapies and predict patient outcomes. About NEUVOGEN NEUVOGEN, Inc. is an immune-oncology company focused on whole cell cancer vaccine therapies. NEUVOGEN believes its cancer vaccines have the broadest combination of tumor associated antigens and tumor specific antigens ever delivered in a cancer vaccine and as a result can directly target a greater percentage of cancer cells in a solid tumor than any previous cancer vaccine. Based in San Diego, California, NEUVOGEN's goal is to develop therapeutic cancer vaccines that activate the body's immune system to eradicate solid tumors and meaningfully extend the lives of patients while limiting side effects. To learn more, visit . For further information please contact: ImaginAb Ian Wilson info@imaginab.com NEUVOGEN Cyrus Arman partnering@neuvogen.com Christine Dusek media@neuvogen.com View original content to download multimedia: SOURCE ImaginAb, Inc.